|2:00 pm - 5:00 pm||Arrival and Check-in|
|3:30 pm - 3:45 pm||Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair|
|3:45 pm - 4:30 pm||Keynote Session: Antibody Modifications to Improve
|This session of the program will focus
on discussing some of the major structural
features that are naturally present in
the antibody repertoire and how these can
inform the rational
design of therapeutic antibodies.|
|Discussion Leader: Kristi Baker (University of Alberta, Canada)|
|3:45 pm - 4:15 pm||George Georgiou (The University of Texas at Austin, USA)|
"Applied Immunology and the Development of Antibody Therapeutics"
|4:15 pm - 4:30 pm||Discussion|
|4:30 pm - 6:00 pm||Poster Session|
|7:30 pm - 9:30 pm||Pathogenicity and Therapy - Dual Role for Ig in Disease|
|In this session,
speakers will present their work investigating the role of IgG and IgG immune
complexes on the onset, progression and treatment of disease.|
|Discussion Leader: Ambily Abraham (Indian Institute of Science, India)|
|7:30 pm - 7:50 pm||Kaitlin Sawatzki (Boston University, USA)|
"Non-Specific Activation of Autoreactive B Cells After Anthrax Vaccination Delays Protection"
|7:50 pm - 8:00 pm||Discussion|
|8:00 pm - 8:20 pm||Malin Bern (University of Oslo, Norway)|
"Engineering of Albumin for Improved FcRn-Mediated Transcytosis"
|8:20 pm - 8:30 pm||Discussion|
|8:30 pm - 8:50 pm||Karin van Schie (Sanquin, The Netherlands)|
"The Biological Effect of Immune Complexes in Infusion Reactions Towards Infliximab"
|8:50 pm - 9:00 pm||Discussion|
|9:00 pm - 9:20 pm||Willem Falkenburg (Sanquin Research, The Netherlands)|
"Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Hinge Neo-Epitopes and Can Serve as Targets for Rheumatoid Factors"
|9:20 pm - 9:30 pm||Discussion|
|7:30 am - 8:30 am||Breakfast|
|9:00 am - 11:00 am||Antibody Engineering for Therapeutic Optimization|
|This session will cover receptor discovery, antibody
discovery and engineering methods that are currently being tested for use to
enhance half-life or therapeutic antibody function.|
|Discussion Leader: Martin McAdam (Oslo University Hospital, Rikshospitalet, Norway)|
|9:00 am - 9:20 am||Gillian Dekkers (Sanquin Blood Supply, The Netherlands)|
"Elucidation of the Functional Consequences of Naturally Occurring Glycan Changes in Humoral IgG Responses Through Glyco-Engineering"
|9:20 am - 9:30 am||Discussion|
|9:30 am - 9:50 am||Fleur van de Bovenkamp (Sanquin Research, The Netherlands)|
"Fab Glycosylation Represents an Additional Mechanism of Antibody Diversification that Modulates Antigen Binding"
|9:50 am - 10:00 am||Discussion|
|10:00 am - 10:20 am||Ning Zhao (Colorado State University, USA)|
"Selection of Nanomolar Affinity Binding Proteins for Active Tuberculosis Diagnosis from an Sso7d Alternative Scaffold Phage Display Library"
|10:20 am - 10:30 am||Discussion|
|10:30 am - 10:50 am||Michal Pyzik (Brigham and Women's Hospital, USA)|
"Identification of a Novel FcRn Ligand"
|10:50 am - 11:00 am||Discussion|
|11:00 am - 12:30 pm||Poster Session|
|Coffee will be served in the poster area from 11:00 am - 11:30 am|
|1:30 pm - 2:30 pm||Mentorship Component: Career Panel|
|Discussion Leader: Anja Lux (University of Erlangen-Nurnberg, Germany)|
|1:30 pm - 2:30 pm||Panel Discussion|
|"How to Begin a Career in Industry vs Academia"|
- Richard Blumberg (Brigham and Women's Hospital / Harvard Medical School, USA)
- Paul Carter (Genentech, Inc., USA)
- Leo James (Medical Research Council, United Kingdom)
- Janine Schuurman (Genmab, The Netherlands)
|2:30 pm - 3:00 pm||Evaluation Period|
|Fill in GRS Evaluation Forms|
|3:00 pm||Seminar Concludes|